- Conditions
- Wilson Disease
- Interventions
- ALXN1840, SoC Therapy
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Wilson Disease
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Wilson Disease
- Interventions
- NCC-Sp Assay
- Diagnostic Test
- Lead sponsor
- Orphalan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 9
- States / cities
- Sacramento, California • New Haven, Connecticut • Miami, Florida + 6 more
- Conditions
- Cystinuria
- Interventions
- Tiopronin 1g per day, Tiopronin 2g per day, Tiopronin 3g per day
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Arteriovenous Fistula Occlusion
- Interventions
- Placebo, Ascorbic Acid, Cuprimine Oral Product
- Drug
- Lead sponsor
- Southeast Renal Research Institute
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chattanooga, Tennessee
- Conditions
- Wilson Disease
- Interventions
- Standard of Care Medications
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Wilson's Disease
- Interventions
- TETA 4HCl formulation, D-Penicillamine
- Drug
- Lead sponsor
- Orphalan
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Denver, Colorado • New Haven, Connecticut • Ann Arbor, Michigan
- Conditions
- Wilson Disease
- Interventions
- Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60), TETA 4HCL (60-<W108)
- Drug
- Lead sponsor
- Orphalan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cystinuria
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 8 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- penicillamine, radiation therapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Lead Poisoning, Vitamin D Deficiency
- Interventions
- d-penicillamine, placebo
- Device · Drug
- Lead sponsor
- FDA Office of Orphan Products Development
- Federal
- Eligibility
- 6 Months to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts